Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV521 in an RSV human challenge model
2017-001282-24Phase 2Completed
- Sponsor
- ReViral
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sisunatovir in respiratory syncytial virus disease (RSV) (4 arms), sponsored by ReViral. Primary endpoint: RSV viral load AUC (primary). Started May 2017; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-001282-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001282-24.